Profile data is unavailable for this security.
About the company
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops immunotherapies to transform cancer care. The Company’s lead drug candidate, Bria-IMT, is a cell-based patented immunotherapy that stimulates a patient’s own cancer fighting cells to attack and destroy breast cancer tumors. The Company is advancing its targeted immunotherapy program by prioritizing a Phase II clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor. The Company is focused on conducting a Phase I/IIa clinical trial of Bria-IMT in a combination study with Incyte’s immune PD-1 inhibitor, retifanlimab, in advanced breast cancer. The Company is also developing Bria-OTS, an off-the-shelf personalized approach to whole cell cancer immunotherapy. The Bria-OTS immunotherapy is based on a patient’s HLA-type. Its pipeline also includes Bria-Pros, Bria-Lung, Bria-Mel and sCD80, which are in development to treat various cancers.
- Revenue in CAD (TTM)0.00
- Net income in CAD-8.18m
- Incorporated2006
- Employees5.00
- LocationBriacell Therapeutics Corp3rd FloorBellevue Centre,, 235-15th StrWEST VANCOUVER V7T 2X1CanadaCAN
- Phone+1 (604) 921-1810
- Fax+1 (604) 921-1898
- Websitehttps://briacell.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Telo Genomics Corp | 0.00 | -2.97m | 14.17m | -- | -- | 22.60 | -- | -- | -0.0434 | -0.0434 | 0.00 | 0.0084 | 0.00 | -- | -- | -- | -323.36 | -85.03 | -407.98 | -113.86 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -33.66 | -- | 24.41 | -- |
Resverlogix Corp | 0.00 | -13.97m | 15.16m | 18.00 | -- | -- | -- | -- | -0.0542 | -0.0542 | 0.00 | -0.3632 | 0.00 | -- | -- | 0.00 | -133.25 | -- | -- | -- | -- | -- | -- | -- | 0.0359 | -1.10 | -- | -- | -- | -- | -363.74 | -- | -- | -- |
AEterna Zentaris Inc. | 3.24m | -24.62m | 18.98m | 21.00 | -- | 0.4255 | -- | 5.86 | -20.28 | -20.28 | 2.67 | 14.57 | 0.0572 | 1.52 | 6.36 | -- | -43.46 | -26.24 | -50.57 | -30.34 | 90.69 | 83.68 | -760.32 | -300.31 | 5.93 | -- | 0.0177 | -- | -20.25 | -30.06 | 27.17 | -- | 16.12 | -- |
Kane Biotech Inc | 165.60k | -4.94m | 19.12m | -- | -- | -- | -- | 115.44 | -0.0383 | -0.0399 | 0.0013 | -0.089 | 0.0294 | 0.085 | 1.25 | -- | -87.75 | -77.89 | -- | -- | 73.29 | 43.27 | -2,984.41 | -241.85 | 0.2957 | -2.88 | -- | -- | -94.42 | -20.26 | -17.29 | -- | -19.41 | -- |
Briacell Therapeutics Corp | 0.00 | -8.18m | 25.83m | 5.00 | -- | -- | -- | -- | -0.5337 | -0.5337 | 0.00 | -0.5091 | 0.00 | -- | -- | -- | -33.97 | -59.37 | -43.50 | -63.11 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 24.35 | -- | -- | -- |
Thiogenesis Therapeutics Corp | 0.00 | -4.71m | 30.94m | -- | -- | 5.79 | -- | -- | -0.1173 | -0.1173 | 0.00 | 0.1175 | 0.00 | -- | -- | -- | -85.31 | -- | -90.24 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- |
MustGrow Biologics Corp | 4.71m | -665.06k | 36.75m | 0.00 | -- | 8.11 | -- | 7.80 | -0.0134 | -0.0134 | 0.0936 | 0.0912 | 0.7632 | -- | 45.31 | -- | -10.77 | -50.41 | -14.00 | -59.28 | -- | -- | -14.11 | -298.73 | -- | -- | 0.1393 | -- | 72,619.13 | 372.54 | 87.84 | -- | -- | -- |